Six years ago, when Daiichi Sankyo, the Japanese pharmaceutical giant, concluded the biggest ever foreign acquisition of an Indian manufacturing company by any group in a $4.2 billion cash deal buying the entire 34.82 per cent stake of Malvinder ... The Echo Of India, 6 days ago
Ranbaxy to be sold to Sun Pharma - Healthcare Finance News, 1 week ago
Ranbaxy: Lessons and Opportunities - PharmaceuticalProcessing, 1 week ago
/PRNewswire/ -- Daiichi Sankyo, Inc. announced today that Ken Keller will join the company as President of its Commercial operations in the United States starting May 1, 2014. In his role, Mr. Keller will be responsible for leading marketing, sales, ...BusinessWeek, 2 days ago Ken Keller Named President, U.S. Commercial, Daiichi Sankyo, Inc. BioSpace, 2 days ago
Japanese innovator drugmaker Daiichi Sankyo bought Ranbaxy in 2008 for $4.6 billion with an intention to enter the generics space by acquiring the largest Indian pharma company. However, it faced daunting challenges in the pursuit. A series of ...Economic Times, 1 week ago Daiichi Sankyo Partners With UCSF To Develop Neurodegenerative Drugs Bioresearch Online, 1 week ago Daiichi Sankyo, UCSF strike deal to combat neurodegeneration Fierce Biotech Research, 1 week ago Series of import bans, loss of credibility made Daiichi cut and run? Economic Times, 1 week ago
DAIICHI SANKYO : Announcement Regarding Merger Between Sun Pharma and Daiichi Sankyo's Subsidiary Ranbaxy and Resulting Change in Subsidiary
For Immediate Release 2014.04.11 Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please address inquiries to Noriaki Ishida, Corporate ...4 Traders, 1 week ago Top heads to roll soon at Ranbaxy Business Standard India, 1 week ago Announcement Regarding Merger Between Sun Pharma and Daiichi Sankyo's Subsidiary Ranbaxy and Resulting Change in Subsidiary FirstWord Pharma, 1 week ago DAIICHI SANKYO : Agrees to Vote its Shares in Ranbaxy in Favor of Sun Pharma's Acquisition 4 Traders, 2 weeks ago
Sun Pharmaceuticals proposal to acquire Ranbaxy Laboratories is good for the ailing company, which now has a better chance to come out of the mess it is in, according to industry leaders and experts. VCCircle spoke to a cross section of third ...VC Circle, 1 week ago
By Estel Grace Masangkay Daiichi Sankyo announced that it has initiated enrollment of patients into the multinational Phase III study ENSURE-AF evaluating the safety and efficacy of edoxaban against enoxaparin and warfarin. The ENSURE-AF is a ...Pharmaceutical Online, 2 weeks ago Daiichi Sankyo initiates patient enrollment in Phase III NVAF study Individual.com, 2 weeks ago
Daiichi Sankyo the parent company of Ranbaxy Laboratories has temporarily suspended shipments of all active pharmaceutical ingredients (API) produced in Toansa and Dewas plants for Ranbaxy.Money Control, 1 month ago Ranbaxy suspends API shipments from Toansa, Dewas plants Deccan Herald, 1 month ago Ranbaxy suspends drug ingredient shipments from two plants Jagran Post, 1 month ago
DAIICHI SANKYO : Once-Daily Edoxaban Evaluated in Two Subgroup Analyses of East Asian Patients from the Largest Comparative Phase 3 Trials of a Novel Oral...
Once-Daily Edoxaban Evaluated in Two Subgroup Analyses of East Asian Patients from the Largest Comparative Phase 3 Trials of a Novel Oral Anticoagulant By a News Reporter-Staff News Editor at China Weekly News -- Daiichi Sankyo Company, Limited ...4 Traders, 2 weeks ago DAIICHI SANKYO : Initiates Phase 3 ENSURE-AF Study, Investigating Once-Daily Edoxaban in Patients with Atrial Fibrillation Undergoing Cardioversion 4 Traders, 2 weeks ago Daiichi Sankyo Initiates Phase 3 ENSURE-AF Study, Investigating Once-Daily Edoxaban in Patients with Atrial Fibrillation Undergoing Cardioversion TMC Net, 2 weeks ago
By Grab Media, a blinkx company Daiichi Sankyo is giving up control of Ranbaxy Laboratories to Sun Pharma for $3.2 billion. Breakingviews' Peter Thal Larsen says it serves as a reminder of what can go wrong in overseas ventures. recommend this ...IT Business Net, 1 week ago
The takeover of Daiichi Sankyo-owned Ranbaxy, India’s largest pharmaceutical firm, by Sun Pharma in an all-stock deal worth nearly $4 billion is not only the largest deal in pharma in Asia but has catapulted Sun Pharma to becoming the world’s fifth ...Asian Age, 1 week ago
on your WebpageAdd Widget >Get your members hooked!